Immuno-inflammatory rheumatic diseases and COVID-19: analysis of clinical outcomes according to the data of the register of patients of the Novosibirsk region receiving therapy with genetically engineered biological drugs
Background. Currently, observations are accumulating indicating the negative effect of therapy with a number of biologic disease-modifying anti-rheumatic drugs (bDMARDs) drugs on the course of COVID-19. These facts determine the relevance of studying the factors of severe course and unfavorable outc...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Maxim A. Korolev [verfasserIn] Elena A. Letyagina [verfasserIn] Alexey E. Sizikov [verfasserIn] Larisa A. Bogoderova [verfasserIn] Yuliya B. Ubshaeva [verfasserIn] Vitaly O. Omelchenko [verfasserIn] Anna A. Akimova [verfasserIn] Arsen A. Mullagaliev [verfasserIn] Oksana A. Chumasova [verfasserIn] Yuliya D. Kurochkina [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Russisch |
| Erschienen: |
2022 |
|---|
| Schlagwörter: |
|---|
| Übergeordnetes Werk: |
In: Терапевтический архив - "Consilium Medicum" Publishing house, 2018, 94(2022), 5, Seite 636-641 |
|---|---|
| Übergeordnetes Werk: |
volume:94 ; year:2022 ; number:5 ; pages:636-641 |
| Links: |
Link aufrufen |
|---|
| DOI / URN: |
10.26442/00403660.2022.05.201502 |
|---|
| Katalog-ID: |
DOAJ043310230 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ043310230 | ||
| 003 | DE-627 | ||
| 005 | 20230308071348.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230227s2022 xx |||||o 00| ||rus c | ||
| 024 | 7 | |a 10.26442/00403660.2022.05.201502 |2 doi | |
| 035 | |a (DE-627)DOAJ043310230 | ||
| 035 | |a (DE-599)DOAJ197bff1aea7140f6af517173e9570920 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a rus | ||
| 100 | 0 | |a Maxim A. Korolev |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Immuno-inflammatory rheumatic diseases and COVID-19: analysis of clinical outcomes according to the data of the register of patients of the Novosibirsk region receiving therapy with genetically engineered biological drugs |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Background. Currently, observations are accumulating indicating the negative effect of therapy with a number of biologic disease-modifying anti-rheumatic drugs (bDMARDs) drugs on the course of COVID-19. These facts determine the relevance of studying the factors of severe course and unfavorable outcome in immuno-inflammatory rheumatic diseases (IIRD) patients treated with bDMARDs in order to develop tactics for managing this category of patients in a pandemic. Aim. To evaluate the influence of clinical and demographic factors on the risk of development, severity of the course and clinical outcomes of a new coronavirus infection in patients suffering from IIRD and receiving therapy with genetically engineered biological drugs. Materials and methods. A retrospective analysis of the database of the register of patients with IIRD receiving bDMARDs in the Novosibirsk region was performed, which included 318 patients, 94 of whom had indications of having suffered viral infection/pneumonia for the period from 01.04.2020 to 31.12.2020. Results. According to the data obtained, at the time of the analysis, 94 people out of 318 patients with IIRD had a new coronavirus infection. Most (53%) of the patients had a mild infection. At the same time, the nosological form, the use of anti-rheumatic drugs and glucocorticoids did not increase the risks of severe coronavirus infection. When using bDMARDs, only anti-B-cell therapy (rituximab) associated with statistically significant increase in the risk of severe/extremely severe COVID-19. The mortality rate according to the analysis of the register was 6,38%. Conclusion. Patients with IIRD have a high risk of severe coronavirus infection, while the severity of the disease is associated with the type of therapy performed. | ||
| 650 | 4 | |a covid-19 | |
| 650 | 4 | |a immuno-inflammatory rheumatic diseases | |
| 650 | 4 | |a mortality | |
| 650 | 4 | |a biologic disease-modifying anti-rheumatic drugs | |
| 653 | 0 | |a Medicine | |
| 653 | 0 | |a R | |
| 700 | 0 | |a Elena A. Letyagina |e verfasserin |4 aut | |
| 700 | 0 | |a Alexey E. Sizikov |e verfasserin |4 aut | |
| 700 | 0 | |a Larisa A. Bogoderova |e verfasserin |4 aut | |
| 700 | 0 | |a Yuliya B. Ubshaeva |e verfasserin |4 aut | |
| 700 | 0 | |a Vitaly O. Omelchenko |e verfasserin |4 aut | |
| 700 | 0 | |a Anna A. Akimova |e verfasserin |4 aut | |
| 700 | 0 | |a Arsen A. Mullagaliev |e verfasserin |4 aut | |
| 700 | 0 | |a Oksana A. Chumasova |e verfasserin |4 aut | |
| 700 | 0 | |a Yuliya D. Kurochkina |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Терапевтический архив |d "Consilium Medicum" Publishing house, 2018 |g 94(2022), 5, Seite 636-641 |w (DE-627)1760620270 |x 23095342 |7 nnns |
| 773 | 1 | 8 | |g volume:94 |g year:2022 |g number:5 |g pages:636-641 |
| 856 | 4 | 0 | |u https://doi.org/10.26442/00403660.2022.05.201502 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/197bff1aea7140f6af517173e9570920 |z kostenfrei |
| 856 | 4 | 0 | |u https://ter-arkhiv.ru/0040-3660/article/viewFile/108780/82895 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/0040-3660 |y Journal toc |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2309-5342 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 94 |j 2022 |e 5 |h 636-641 | ||
| author_variant |
m a k mak e a l eal a e s aes l a b lab y b u ybu v o o voo a a a aaa a a m aam o a c oac y d k ydk |
|---|---|
| matchkey_str |
article:23095342:2022----::muonlmaoyhuaidsaeadoi1aayiociiaotoeacrigohdtoteeitrfainsfhnvsbrkeineev |
| hierarchy_sort_str |
2022 |
| publishDate |
2022 |
| allfields |
10.26442/00403660.2022.05.201502 doi (DE-627)DOAJ043310230 (DE-599)DOAJ197bff1aea7140f6af517173e9570920 DE-627 ger DE-627 rakwb rus Maxim A. Korolev verfasserin aut Immuno-inflammatory rheumatic diseases and COVID-19: analysis of clinical outcomes according to the data of the register of patients of the Novosibirsk region receiving therapy with genetically engineered biological drugs 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Background. Currently, observations are accumulating indicating the negative effect of therapy with a number of biologic disease-modifying anti-rheumatic drugs (bDMARDs) drugs on the course of COVID-19. These facts determine the relevance of studying the factors of severe course and unfavorable outcome in immuno-inflammatory rheumatic diseases (IIRD) patients treated with bDMARDs in order to develop tactics for managing this category of patients in a pandemic. Aim. To evaluate the influence of clinical and demographic factors on the risk of development, severity of the course and clinical outcomes of a new coronavirus infection in patients suffering from IIRD and receiving therapy with genetically engineered biological drugs. Materials and methods. A retrospective analysis of the database of the register of patients with IIRD receiving bDMARDs in the Novosibirsk region was performed, which included 318 patients, 94 of whom had indications of having suffered viral infection/pneumonia for the period from 01.04.2020 to 31.12.2020. Results. According to the data obtained, at the time of the analysis, 94 people out of 318 patients with IIRD had a new coronavirus infection. Most (53%) of the patients had a mild infection. At the same time, the nosological form, the use of anti-rheumatic drugs and glucocorticoids did not increase the risks of severe coronavirus infection. When using bDMARDs, only anti-B-cell therapy (rituximab) associated with statistically significant increase in the risk of severe/extremely severe COVID-19. The mortality rate according to the analysis of the register was 6,38%. Conclusion. Patients with IIRD have a high risk of severe coronavirus infection, while the severity of the disease is associated with the type of therapy performed. covid-19 immuno-inflammatory rheumatic diseases mortality biologic disease-modifying anti-rheumatic drugs Medicine R Elena A. Letyagina verfasserin aut Alexey E. Sizikov verfasserin aut Larisa A. Bogoderova verfasserin aut Yuliya B. Ubshaeva verfasserin aut Vitaly O. Omelchenko verfasserin aut Anna A. Akimova verfasserin aut Arsen A. Mullagaliev verfasserin aut Oksana A. Chumasova verfasserin aut Yuliya D. Kurochkina verfasserin aut In Терапевтический архив "Consilium Medicum" Publishing house, 2018 94(2022), 5, Seite 636-641 (DE-627)1760620270 23095342 nnns volume:94 year:2022 number:5 pages:636-641 https://doi.org/10.26442/00403660.2022.05.201502 kostenfrei https://doaj.org/article/197bff1aea7140f6af517173e9570920 kostenfrei https://ter-arkhiv.ru/0040-3660/article/viewFile/108780/82895 kostenfrei https://doaj.org/toc/0040-3660 Journal toc kostenfrei https://doaj.org/toc/2309-5342 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 94 2022 5 636-641 |
| spelling |
10.26442/00403660.2022.05.201502 doi (DE-627)DOAJ043310230 (DE-599)DOAJ197bff1aea7140f6af517173e9570920 DE-627 ger DE-627 rakwb rus Maxim A. Korolev verfasserin aut Immuno-inflammatory rheumatic diseases and COVID-19: analysis of clinical outcomes according to the data of the register of patients of the Novosibirsk region receiving therapy with genetically engineered biological drugs 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Background. Currently, observations are accumulating indicating the negative effect of therapy with a number of biologic disease-modifying anti-rheumatic drugs (bDMARDs) drugs on the course of COVID-19. These facts determine the relevance of studying the factors of severe course and unfavorable outcome in immuno-inflammatory rheumatic diseases (IIRD) patients treated with bDMARDs in order to develop tactics for managing this category of patients in a pandemic. Aim. To evaluate the influence of clinical and demographic factors on the risk of development, severity of the course and clinical outcomes of a new coronavirus infection in patients suffering from IIRD and receiving therapy with genetically engineered biological drugs. Materials and methods. A retrospective analysis of the database of the register of patients with IIRD receiving bDMARDs in the Novosibirsk region was performed, which included 318 patients, 94 of whom had indications of having suffered viral infection/pneumonia for the period from 01.04.2020 to 31.12.2020. Results. According to the data obtained, at the time of the analysis, 94 people out of 318 patients with IIRD had a new coronavirus infection. Most (53%) of the patients had a mild infection. At the same time, the nosological form, the use of anti-rheumatic drugs and glucocorticoids did not increase the risks of severe coronavirus infection. When using bDMARDs, only anti-B-cell therapy (rituximab) associated with statistically significant increase in the risk of severe/extremely severe COVID-19. The mortality rate according to the analysis of the register was 6,38%. Conclusion. Patients with IIRD have a high risk of severe coronavirus infection, while the severity of the disease is associated with the type of therapy performed. covid-19 immuno-inflammatory rheumatic diseases mortality biologic disease-modifying anti-rheumatic drugs Medicine R Elena A. Letyagina verfasserin aut Alexey E. Sizikov verfasserin aut Larisa A. Bogoderova verfasserin aut Yuliya B. Ubshaeva verfasserin aut Vitaly O. Omelchenko verfasserin aut Anna A. Akimova verfasserin aut Arsen A. Mullagaliev verfasserin aut Oksana A. Chumasova verfasserin aut Yuliya D. Kurochkina verfasserin aut In Терапевтический архив "Consilium Medicum" Publishing house, 2018 94(2022), 5, Seite 636-641 (DE-627)1760620270 23095342 nnns volume:94 year:2022 number:5 pages:636-641 https://doi.org/10.26442/00403660.2022.05.201502 kostenfrei https://doaj.org/article/197bff1aea7140f6af517173e9570920 kostenfrei https://ter-arkhiv.ru/0040-3660/article/viewFile/108780/82895 kostenfrei https://doaj.org/toc/0040-3660 Journal toc kostenfrei https://doaj.org/toc/2309-5342 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 94 2022 5 636-641 |
| allfields_unstemmed |
10.26442/00403660.2022.05.201502 doi (DE-627)DOAJ043310230 (DE-599)DOAJ197bff1aea7140f6af517173e9570920 DE-627 ger DE-627 rakwb rus Maxim A. Korolev verfasserin aut Immuno-inflammatory rheumatic diseases and COVID-19: analysis of clinical outcomes according to the data of the register of patients of the Novosibirsk region receiving therapy with genetically engineered biological drugs 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Background. Currently, observations are accumulating indicating the negative effect of therapy with a number of biologic disease-modifying anti-rheumatic drugs (bDMARDs) drugs on the course of COVID-19. These facts determine the relevance of studying the factors of severe course and unfavorable outcome in immuno-inflammatory rheumatic diseases (IIRD) patients treated with bDMARDs in order to develop tactics for managing this category of patients in a pandemic. Aim. To evaluate the influence of clinical and demographic factors on the risk of development, severity of the course and clinical outcomes of a new coronavirus infection in patients suffering from IIRD and receiving therapy with genetically engineered biological drugs. Materials and methods. A retrospective analysis of the database of the register of patients with IIRD receiving bDMARDs in the Novosibirsk region was performed, which included 318 patients, 94 of whom had indications of having suffered viral infection/pneumonia for the period from 01.04.2020 to 31.12.2020. Results. According to the data obtained, at the time of the analysis, 94 people out of 318 patients with IIRD had a new coronavirus infection. Most (53%) of the patients had a mild infection. At the same time, the nosological form, the use of anti-rheumatic drugs and glucocorticoids did not increase the risks of severe coronavirus infection. When using bDMARDs, only anti-B-cell therapy (rituximab) associated with statistically significant increase in the risk of severe/extremely severe COVID-19. The mortality rate according to the analysis of the register was 6,38%. Conclusion. Patients with IIRD have a high risk of severe coronavirus infection, while the severity of the disease is associated with the type of therapy performed. covid-19 immuno-inflammatory rheumatic diseases mortality biologic disease-modifying anti-rheumatic drugs Medicine R Elena A. Letyagina verfasserin aut Alexey E. Sizikov verfasserin aut Larisa A. Bogoderova verfasserin aut Yuliya B. Ubshaeva verfasserin aut Vitaly O. Omelchenko verfasserin aut Anna A. Akimova verfasserin aut Arsen A. Mullagaliev verfasserin aut Oksana A. Chumasova verfasserin aut Yuliya D. Kurochkina verfasserin aut In Терапевтический архив "Consilium Medicum" Publishing house, 2018 94(2022), 5, Seite 636-641 (DE-627)1760620270 23095342 nnns volume:94 year:2022 number:5 pages:636-641 https://doi.org/10.26442/00403660.2022.05.201502 kostenfrei https://doaj.org/article/197bff1aea7140f6af517173e9570920 kostenfrei https://ter-arkhiv.ru/0040-3660/article/viewFile/108780/82895 kostenfrei https://doaj.org/toc/0040-3660 Journal toc kostenfrei https://doaj.org/toc/2309-5342 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 94 2022 5 636-641 |
| allfieldsGer |
10.26442/00403660.2022.05.201502 doi (DE-627)DOAJ043310230 (DE-599)DOAJ197bff1aea7140f6af517173e9570920 DE-627 ger DE-627 rakwb rus Maxim A. Korolev verfasserin aut Immuno-inflammatory rheumatic diseases and COVID-19: analysis of clinical outcomes according to the data of the register of patients of the Novosibirsk region receiving therapy with genetically engineered biological drugs 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Background. Currently, observations are accumulating indicating the negative effect of therapy with a number of biologic disease-modifying anti-rheumatic drugs (bDMARDs) drugs on the course of COVID-19. These facts determine the relevance of studying the factors of severe course and unfavorable outcome in immuno-inflammatory rheumatic diseases (IIRD) patients treated with bDMARDs in order to develop tactics for managing this category of patients in a pandemic. Aim. To evaluate the influence of clinical and demographic factors on the risk of development, severity of the course and clinical outcomes of a new coronavirus infection in patients suffering from IIRD and receiving therapy with genetically engineered biological drugs. Materials and methods. A retrospective analysis of the database of the register of patients with IIRD receiving bDMARDs in the Novosibirsk region was performed, which included 318 patients, 94 of whom had indications of having suffered viral infection/pneumonia for the period from 01.04.2020 to 31.12.2020. Results. According to the data obtained, at the time of the analysis, 94 people out of 318 patients with IIRD had a new coronavirus infection. Most (53%) of the patients had a mild infection. At the same time, the nosological form, the use of anti-rheumatic drugs and glucocorticoids did not increase the risks of severe coronavirus infection. When using bDMARDs, only anti-B-cell therapy (rituximab) associated with statistically significant increase in the risk of severe/extremely severe COVID-19. The mortality rate according to the analysis of the register was 6,38%. Conclusion. Patients with IIRD have a high risk of severe coronavirus infection, while the severity of the disease is associated with the type of therapy performed. covid-19 immuno-inflammatory rheumatic diseases mortality biologic disease-modifying anti-rheumatic drugs Medicine R Elena A. Letyagina verfasserin aut Alexey E. Sizikov verfasserin aut Larisa A. Bogoderova verfasserin aut Yuliya B. Ubshaeva verfasserin aut Vitaly O. Omelchenko verfasserin aut Anna A. Akimova verfasserin aut Arsen A. Mullagaliev verfasserin aut Oksana A. Chumasova verfasserin aut Yuliya D. Kurochkina verfasserin aut In Терапевтический архив "Consilium Medicum" Publishing house, 2018 94(2022), 5, Seite 636-641 (DE-627)1760620270 23095342 nnns volume:94 year:2022 number:5 pages:636-641 https://doi.org/10.26442/00403660.2022.05.201502 kostenfrei https://doaj.org/article/197bff1aea7140f6af517173e9570920 kostenfrei https://ter-arkhiv.ru/0040-3660/article/viewFile/108780/82895 kostenfrei https://doaj.org/toc/0040-3660 Journal toc kostenfrei https://doaj.org/toc/2309-5342 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 94 2022 5 636-641 |
| allfieldsSound |
10.26442/00403660.2022.05.201502 doi (DE-627)DOAJ043310230 (DE-599)DOAJ197bff1aea7140f6af517173e9570920 DE-627 ger DE-627 rakwb rus Maxim A. Korolev verfasserin aut Immuno-inflammatory rheumatic diseases and COVID-19: analysis of clinical outcomes according to the data of the register of patients of the Novosibirsk region receiving therapy with genetically engineered biological drugs 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Background. Currently, observations are accumulating indicating the negative effect of therapy with a number of biologic disease-modifying anti-rheumatic drugs (bDMARDs) drugs on the course of COVID-19. These facts determine the relevance of studying the factors of severe course and unfavorable outcome in immuno-inflammatory rheumatic diseases (IIRD) patients treated with bDMARDs in order to develop tactics for managing this category of patients in a pandemic. Aim. To evaluate the influence of clinical and demographic factors on the risk of development, severity of the course and clinical outcomes of a new coronavirus infection in patients suffering from IIRD and receiving therapy with genetically engineered biological drugs. Materials and methods. A retrospective analysis of the database of the register of patients with IIRD receiving bDMARDs in the Novosibirsk region was performed, which included 318 patients, 94 of whom had indications of having suffered viral infection/pneumonia for the period from 01.04.2020 to 31.12.2020. Results. According to the data obtained, at the time of the analysis, 94 people out of 318 patients with IIRD had a new coronavirus infection. Most (53%) of the patients had a mild infection. At the same time, the nosological form, the use of anti-rheumatic drugs and glucocorticoids did not increase the risks of severe coronavirus infection. When using bDMARDs, only anti-B-cell therapy (rituximab) associated with statistically significant increase in the risk of severe/extremely severe COVID-19. The mortality rate according to the analysis of the register was 6,38%. Conclusion. Patients with IIRD have a high risk of severe coronavirus infection, while the severity of the disease is associated with the type of therapy performed. covid-19 immuno-inflammatory rheumatic diseases mortality biologic disease-modifying anti-rheumatic drugs Medicine R Elena A. Letyagina verfasserin aut Alexey E. Sizikov verfasserin aut Larisa A. Bogoderova verfasserin aut Yuliya B. Ubshaeva verfasserin aut Vitaly O. Omelchenko verfasserin aut Anna A. Akimova verfasserin aut Arsen A. Mullagaliev verfasserin aut Oksana A. Chumasova verfasserin aut Yuliya D. Kurochkina verfasserin aut In Терапевтический архив "Consilium Medicum" Publishing house, 2018 94(2022), 5, Seite 636-641 (DE-627)1760620270 23095342 nnns volume:94 year:2022 number:5 pages:636-641 https://doi.org/10.26442/00403660.2022.05.201502 kostenfrei https://doaj.org/article/197bff1aea7140f6af517173e9570920 kostenfrei https://ter-arkhiv.ru/0040-3660/article/viewFile/108780/82895 kostenfrei https://doaj.org/toc/0040-3660 Journal toc kostenfrei https://doaj.org/toc/2309-5342 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 94 2022 5 636-641 |
| language |
Russian |
| source |
In Терапевтический архив 94(2022), 5, Seite 636-641 volume:94 year:2022 number:5 pages:636-641 |
| sourceStr |
In Терапевтический архив 94(2022), 5, Seite 636-641 volume:94 year:2022 number:5 pages:636-641 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
covid-19 immuno-inflammatory rheumatic diseases mortality biologic disease-modifying anti-rheumatic drugs Medicine R |
| isfreeaccess_bool |
true |
| container_title |
Терапевтический архив |
| authorswithroles_txt_mv |
Maxim A. Korolev @@aut@@ Elena A. Letyagina @@aut@@ Alexey E. Sizikov @@aut@@ Larisa A. Bogoderova @@aut@@ Yuliya B. Ubshaeva @@aut@@ Vitaly O. Omelchenko @@aut@@ Anna A. Akimova @@aut@@ Arsen A. Mullagaliev @@aut@@ Oksana A. Chumasova @@aut@@ Yuliya D. Kurochkina @@aut@@ |
| publishDateDaySort_date |
2022-01-01T00:00:00Z |
| hierarchy_top_id |
1760620270 |
| id |
DOAJ043310230 |
| language_de |
russisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ043310230</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230308071348.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230227s2022 xx |||||o 00| ||rus c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.26442/00403660.2022.05.201502</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ043310230</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ197bff1aea7140f6af517173e9570920</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">rus</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Maxim A. Korolev</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Immuno-inflammatory rheumatic diseases and COVID-19: analysis of clinical outcomes according to the data of the register of patients of the Novosibirsk region receiving therapy with genetically engineered biological drugs</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2022</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Background. Currently, observations are accumulating indicating the negative effect of therapy with a number of biologic disease-modifying anti-rheumatic drugs (bDMARDs) drugs on the course of COVID-19. These facts determine the relevance of studying the factors of severe course and unfavorable outcome in immuno-inflammatory rheumatic diseases (IIRD) patients treated with bDMARDs in order to develop tactics for managing this category of patients in a pandemic. Aim. To evaluate the influence of clinical and demographic factors on the risk of development, severity of the course and clinical outcomes of a new coronavirus infection in patients suffering from IIRD and receiving therapy with genetically engineered biological drugs. Materials and methods. A retrospective analysis of the database of the register of patients with IIRD receiving bDMARDs in the Novosibirsk region was performed, which included 318 patients, 94 of whom had indications of having suffered viral infection/pneumonia for the period from 01.04.2020 to 31.12.2020. Results. According to the data obtained, at the time of the analysis, 94 people out of 318 patients with IIRD had a new coronavirus infection. Most (53%) of the patients had a mild infection. At the same time, the nosological form, the use of anti-rheumatic drugs and glucocorticoids did not increase the risks of severe coronavirus infection. When using bDMARDs, only anti-B-cell therapy (rituximab) associated with statistically significant increase in the risk of severe/extremely severe COVID-19. The mortality rate according to the analysis of the register was 6,38%. Conclusion. Patients with IIRD have a high risk of severe coronavirus infection, while the severity of the disease is associated with the type of therapy performed.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">covid-19</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">immuno-inflammatory rheumatic diseases</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">mortality</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">biologic disease-modifying anti-rheumatic drugs</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Medicine</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">R</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Elena A. Letyagina</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Alexey E. Sizikov</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Larisa A. Bogoderova</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Yuliya B. Ubshaeva</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Vitaly O. Omelchenko</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Anna A. Akimova</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Arsen A. Mullagaliev</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Oksana A. Chumasova</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Yuliya D. Kurochkina</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Терапевтический архив</subfield><subfield code="d">"Consilium Medicum" Publishing house, 2018</subfield><subfield code="g">94(2022), 5, Seite 636-641</subfield><subfield code="w">(DE-627)1760620270</subfield><subfield code="x">23095342</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:94</subfield><subfield code="g">year:2022</subfield><subfield code="g">number:5</subfield><subfield code="g">pages:636-641</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.26442/00403660.2022.05.201502</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/197bff1aea7140f6af517173e9570920</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://ter-arkhiv.ru/0040-3660/article/viewFile/108780/82895</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/0040-3660</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2309-5342</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">94</subfield><subfield code="j">2022</subfield><subfield code="e">5</subfield><subfield code="h">636-641</subfield></datafield></record></collection>
|
| author |
Maxim A. Korolev |
| spellingShingle |
Maxim A. Korolev misc covid-19 misc immuno-inflammatory rheumatic diseases misc mortality misc biologic disease-modifying anti-rheumatic drugs misc Medicine misc R Immuno-inflammatory rheumatic diseases and COVID-19: analysis of clinical outcomes according to the data of the register of patients of the Novosibirsk region receiving therapy with genetically engineered biological drugs |
| authorStr |
Maxim A. Korolev |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)1760620270 |
| format |
electronic Article |
| delete_txt_mv |
keep |
| author_role |
aut aut aut aut aut aut aut aut aut aut |
| collection |
DOAJ |
| remote_str |
true |
| illustrated |
Not Illustrated |
| issn |
23095342 |
| topic_title |
Immuno-inflammatory rheumatic diseases and COVID-19: analysis of clinical outcomes according to the data of the register of patients of the Novosibirsk region receiving therapy with genetically engineered biological drugs covid-19 immuno-inflammatory rheumatic diseases mortality biologic disease-modifying anti-rheumatic drugs |
| topic |
misc covid-19 misc immuno-inflammatory rheumatic diseases misc mortality misc biologic disease-modifying anti-rheumatic drugs misc Medicine misc R |
| topic_unstemmed |
misc covid-19 misc immuno-inflammatory rheumatic diseases misc mortality misc biologic disease-modifying anti-rheumatic drugs misc Medicine misc R |
| topic_browse |
misc covid-19 misc immuno-inflammatory rheumatic diseases misc mortality misc biologic disease-modifying anti-rheumatic drugs misc Medicine misc R |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
cr |
| hierarchy_parent_title |
Терапевтический архив |
| hierarchy_parent_id |
1760620270 |
| hierarchy_top_title |
Терапевтический архив |
| isfreeaccess_txt |
true |
| familylinks_str_mv |
(DE-627)1760620270 |
| title |
Immuno-inflammatory rheumatic diseases and COVID-19: analysis of clinical outcomes according to the data of the register of patients of the Novosibirsk region receiving therapy with genetically engineered biological drugs |
| ctrlnum |
(DE-627)DOAJ043310230 (DE-599)DOAJ197bff1aea7140f6af517173e9570920 |
| title_full |
Immuno-inflammatory rheumatic diseases and COVID-19: analysis of clinical outcomes according to the data of the register of patients of the Novosibirsk region receiving therapy with genetically engineered biological drugs |
| author_sort |
Maxim A. Korolev |
| journal |
Терапевтический архив |
| journalStr |
Терапевтический архив |
| lang_code |
rus |
| isOA_bool |
true |
| recordtype |
marc |
| publishDateSort |
2022 |
| contenttype_str_mv |
txt |
| container_start_page |
636 |
| author_browse |
Maxim A. Korolev Elena A. Letyagina Alexey E. Sizikov Larisa A. Bogoderova Yuliya B. Ubshaeva Vitaly O. Omelchenko Anna A. Akimova Arsen A. Mullagaliev Oksana A. Chumasova Yuliya D. Kurochkina |
| container_volume |
94 |
| format_se |
Elektronische Aufsätze |
| author-letter |
Maxim A. Korolev |
| doi_str_mv |
10.26442/00403660.2022.05.201502 |
| author2-role |
verfasserin |
| title_sort |
immuno-inflammatory rheumatic diseases and covid-19: analysis of clinical outcomes according to the data of the register of patients of the novosibirsk region receiving therapy with genetically engineered biological drugs |
| title_auth |
Immuno-inflammatory rheumatic diseases and COVID-19: analysis of clinical outcomes according to the data of the register of patients of the Novosibirsk region receiving therapy with genetically engineered biological drugs |
| abstract |
Background. Currently, observations are accumulating indicating the negative effect of therapy with a number of biologic disease-modifying anti-rheumatic drugs (bDMARDs) drugs on the course of COVID-19. These facts determine the relevance of studying the factors of severe course and unfavorable outcome in immuno-inflammatory rheumatic diseases (IIRD) patients treated with bDMARDs in order to develop tactics for managing this category of patients in a pandemic. Aim. To evaluate the influence of clinical and demographic factors on the risk of development, severity of the course and clinical outcomes of a new coronavirus infection in patients suffering from IIRD and receiving therapy with genetically engineered biological drugs. Materials and methods. A retrospective analysis of the database of the register of patients with IIRD receiving bDMARDs in the Novosibirsk region was performed, which included 318 patients, 94 of whom had indications of having suffered viral infection/pneumonia for the period from 01.04.2020 to 31.12.2020. Results. According to the data obtained, at the time of the analysis, 94 people out of 318 patients with IIRD had a new coronavirus infection. Most (53%) of the patients had a mild infection. At the same time, the nosological form, the use of anti-rheumatic drugs and glucocorticoids did not increase the risks of severe coronavirus infection. When using bDMARDs, only anti-B-cell therapy (rituximab) associated with statistically significant increase in the risk of severe/extremely severe COVID-19. The mortality rate according to the analysis of the register was 6,38%. Conclusion. Patients with IIRD have a high risk of severe coronavirus infection, while the severity of the disease is associated with the type of therapy performed. |
| abstractGer |
Background. Currently, observations are accumulating indicating the negative effect of therapy with a number of biologic disease-modifying anti-rheumatic drugs (bDMARDs) drugs on the course of COVID-19. These facts determine the relevance of studying the factors of severe course and unfavorable outcome in immuno-inflammatory rheumatic diseases (IIRD) patients treated with bDMARDs in order to develop tactics for managing this category of patients in a pandemic. Aim. To evaluate the influence of clinical and demographic factors on the risk of development, severity of the course and clinical outcomes of a new coronavirus infection in patients suffering from IIRD and receiving therapy with genetically engineered biological drugs. Materials and methods. A retrospective analysis of the database of the register of patients with IIRD receiving bDMARDs in the Novosibirsk region was performed, which included 318 patients, 94 of whom had indications of having suffered viral infection/pneumonia for the period from 01.04.2020 to 31.12.2020. Results. According to the data obtained, at the time of the analysis, 94 people out of 318 patients with IIRD had a new coronavirus infection. Most (53%) of the patients had a mild infection. At the same time, the nosological form, the use of anti-rheumatic drugs and glucocorticoids did not increase the risks of severe coronavirus infection. When using bDMARDs, only anti-B-cell therapy (rituximab) associated with statistically significant increase in the risk of severe/extremely severe COVID-19. The mortality rate according to the analysis of the register was 6,38%. Conclusion. Patients with IIRD have a high risk of severe coronavirus infection, while the severity of the disease is associated with the type of therapy performed. |
| abstract_unstemmed |
Background. Currently, observations are accumulating indicating the negative effect of therapy with a number of biologic disease-modifying anti-rheumatic drugs (bDMARDs) drugs on the course of COVID-19. These facts determine the relevance of studying the factors of severe course and unfavorable outcome in immuno-inflammatory rheumatic diseases (IIRD) patients treated with bDMARDs in order to develop tactics for managing this category of patients in a pandemic. Aim. To evaluate the influence of clinical and demographic factors on the risk of development, severity of the course and clinical outcomes of a new coronavirus infection in patients suffering from IIRD and receiving therapy with genetically engineered biological drugs. Materials and methods. A retrospective analysis of the database of the register of patients with IIRD receiving bDMARDs in the Novosibirsk region was performed, which included 318 patients, 94 of whom had indications of having suffered viral infection/pneumonia for the period from 01.04.2020 to 31.12.2020. Results. According to the data obtained, at the time of the analysis, 94 people out of 318 patients with IIRD had a new coronavirus infection. Most (53%) of the patients had a mild infection. At the same time, the nosological form, the use of anti-rheumatic drugs and glucocorticoids did not increase the risks of severe coronavirus infection. When using bDMARDs, only anti-B-cell therapy (rituximab) associated with statistically significant increase in the risk of severe/extremely severe COVID-19. The mortality rate according to the analysis of the register was 6,38%. Conclusion. Patients with IIRD have a high risk of severe coronavirus infection, while the severity of the disease is associated with the type of therapy performed. |
| collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ |
| container_issue |
5 |
| title_short |
Immuno-inflammatory rheumatic diseases and COVID-19: analysis of clinical outcomes according to the data of the register of patients of the Novosibirsk region receiving therapy with genetically engineered biological drugs |
| url |
https://doi.org/10.26442/00403660.2022.05.201502 https://doaj.org/article/197bff1aea7140f6af517173e9570920 https://ter-arkhiv.ru/0040-3660/article/viewFile/108780/82895 https://doaj.org/toc/0040-3660 https://doaj.org/toc/2309-5342 |
| remote_bool |
true |
| author2 |
Elena A. Letyagina Alexey E. Sizikov Larisa A. Bogoderova Yuliya B. Ubshaeva Vitaly O. Omelchenko Anna A. Akimova Arsen A. Mullagaliev Oksana A. Chumasova Yuliya D. Kurochkina |
| author2Str |
Elena A. Letyagina Alexey E. Sizikov Larisa A. Bogoderova Yuliya B. Ubshaeva Vitaly O. Omelchenko Anna A. Akimova Arsen A. Mullagaliev Oksana A. Chumasova Yuliya D. Kurochkina |
| ppnlink |
1760620270 |
| mediatype_str_mv |
c |
| isOA_txt |
true |
| hochschulschrift_bool |
false |
| doi_str |
10.26442/00403660.2022.05.201502 |
| up_date |
2024-07-03T16:51:21.526Z |
| _version_ |
1803577439317655552 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ043310230</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230308071348.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230227s2022 xx |||||o 00| ||rus c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.26442/00403660.2022.05.201502</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ043310230</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ197bff1aea7140f6af517173e9570920</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">rus</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Maxim A. Korolev</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Immuno-inflammatory rheumatic diseases and COVID-19: analysis of clinical outcomes according to the data of the register of patients of the Novosibirsk region receiving therapy with genetically engineered biological drugs</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2022</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Background. Currently, observations are accumulating indicating the negative effect of therapy with a number of biologic disease-modifying anti-rheumatic drugs (bDMARDs) drugs on the course of COVID-19. These facts determine the relevance of studying the factors of severe course and unfavorable outcome in immuno-inflammatory rheumatic diseases (IIRD) patients treated with bDMARDs in order to develop tactics for managing this category of patients in a pandemic. Aim. To evaluate the influence of clinical and demographic factors on the risk of development, severity of the course and clinical outcomes of a new coronavirus infection in patients suffering from IIRD and receiving therapy with genetically engineered biological drugs. Materials and methods. A retrospective analysis of the database of the register of patients with IIRD receiving bDMARDs in the Novosibirsk region was performed, which included 318 patients, 94 of whom had indications of having suffered viral infection/pneumonia for the period from 01.04.2020 to 31.12.2020. Results. According to the data obtained, at the time of the analysis, 94 people out of 318 patients with IIRD had a new coronavirus infection. Most (53%) of the patients had a mild infection. At the same time, the nosological form, the use of anti-rheumatic drugs and glucocorticoids did not increase the risks of severe coronavirus infection. When using bDMARDs, only anti-B-cell therapy (rituximab) associated with statistically significant increase in the risk of severe/extremely severe COVID-19. The mortality rate according to the analysis of the register was 6,38%. Conclusion. Patients with IIRD have a high risk of severe coronavirus infection, while the severity of the disease is associated with the type of therapy performed.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">covid-19</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">immuno-inflammatory rheumatic diseases</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">mortality</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">biologic disease-modifying anti-rheumatic drugs</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Medicine</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">R</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Elena A. Letyagina</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Alexey E. Sizikov</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Larisa A. Bogoderova</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Yuliya B. Ubshaeva</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Vitaly O. Omelchenko</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Anna A. Akimova</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Arsen A. Mullagaliev</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Oksana A. Chumasova</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Yuliya D. Kurochkina</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Терапевтический архив</subfield><subfield code="d">"Consilium Medicum" Publishing house, 2018</subfield><subfield code="g">94(2022), 5, Seite 636-641</subfield><subfield code="w">(DE-627)1760620270</subfield><subfield code="x">23095342</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:94</subfield><subfield code="g">year:2022</subfield><subfield code="g">number:5</subfield><subfield code="g">pages:636-641</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.26442/00403660.2022.05.201502</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/197bff1aea7140f6af517173e9570920</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://ter-arkhiv.ru/0040-3660/article/viewFile/108780/82895</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/0040-3660</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2309-5342</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">94</subfield><subfield code="j">2022</subfield><subfield code="e">5</subfield><subfield code="h">636-641</subfield></datafield></record></collection>
|
| score |
7.401681 |